WeChat in China: How pharma and market researchers can utilise this emerging digital platform
WeChat is the number one mobile communication platform in China. It has a monthly user base of over 1 billion people and now offers a whole host of features including WeChat pay, mini-programs, social networking and games. In today’s fiercely competitive marketplace, it is critical to keep up with global trends in digital communications. In our last webinar, we looked at the rise of WhatsApp in Latin America. Now we ask, can the WeChat platform be leveraged in China in a similar way, as both a means of collecting insights and ultimately, engaging customers?
How we helped our client maximise uptake and fine-tune the marketing strategy for their vaccine product in China
Our client’s vaccine to protect against a condition prevalent in older adults had recently launched and secondary research was required to enable them to understand more about their target healthcare consumer and attitudes to health, well-being and vaccination. They needed to build a complete picture of how consumers are influenced, such as whether they are more influenced by HCP advice or online forums and social media. Furthermore they needed to develop an understanding for other out-of-pocket (OOP) competitor vaccines and what the future healthcare initiatives mean for vaccination in general.
China: How to strategise and win in the world's fastest changing healthcare market
In this paper, our experts Marc Yates, Pei Li Teh and Brett Gardiner discuss the China healthcare reforms which affect pharma and propose how to build the market understanding required to launch a brand effectively in this exciting region.
With a population of 1.4 billion people China has always been an attractive prize to the pharmaceutical industry. However, China has historically been a tough market to crack and few multinational companies have seen a good return on their investment. But in 2019, the 70th anniversary of the communist party’s victory, the outlook has changed completely and now pharma is rushing to leverage the many opportunities that China offers.
China: How to keep up and win in the world's fastest changing healthcare market
China's population will start to shrink in 2023 placing greater weight on the working population who have to support increasing numbers of 65+ year olds. The aging population combined with a surge in non-communicable diseases has led to a higher disease burden and more pressure on an already overstretched healthcare system. Seeking to modernise, China has undertaken a range of reforms.
Webcast: China in the Fast Lane - How to play and win in the world's hottest emerging market
Watch this webcast in which Pei Li Teh and Wan Ling Neo explore China's evolving healthcare environment. In this webcast they highlight the key changes affecting pharma and demonstrate how to build the market understanding required to launch a brand effectively in this exciting region.